Good morning, everyone, and how are you today? We are doing just fine, thank you, as we quickly adjust time zones and prepare for a public speaking exercise at what amounts to Woodstock for pharmacists. Nonetheless, this has not stopped us from the usual routine of foraging for interesting items, although our usual posting will take a hit today and tomorrow, since we have a few meetings before the trek back to the Pharmalot campus. Meanwhile, here are the aforementioned tidbits. Hope your day is smashing and please do keep in touch.

A string of multibillion-dollar pharmaceutical deals announced this week brings us to a record-setting year in which drug makers and biotechs have spent $342 billion snapping up smaller companies to bolster their pipelines, MarketWatch tells us. While the number of U.S. pharmaceutical and biotechnology deals has increased year over year, from 365 in 2018 to 484 so far this year, it’s the size of 2019’s mergers and acquisitions that is notable. This year’s $342 billion in M&A activity far surpasses any other year since 1995.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy